R03AK04 - Salbutamol and Sodium Cromoglicate |
Probably not porphyrinogenic |
PNP |
Rationale
Salbutamol: Rather low dose, in large parts excreted unmetabolised. No data pointing to clinical CYP-interaction. Four references consider it safe.
Ipratropium: Hydrophilic substance, insignificant systemic exposure.
Chemical description
Salbutamol: Adrenergic beta-receptor stimulating agent used in asthma. Administered as salbutamol sulfate in micronized form in inhalation aerosol (2.5-5 mg/dose). No clinical data pointing to CYP-interaction. About 35% of the dose is excreted in unchanged form in urine.
Ipratropiumbromide: A quarternary ammonium compound with anticholinergic properties. used in inhalation aerosol (21-42 µg/dose) as bronchodilator in chronic obstructive pulmonary disease and in asthma. No data pointing to CYP-interaction.
IPNet drug reports
Uneventful use reported in 1 patient with acute porphyria.
Similar drugs
References
| # | Citation details | PubMed ID |
|---|---|---|
| 1. | Prognosis of acute porphyria: occurrence of acute attacks, precipitating factors, and associated diseases.
Kauppinen R, Mustajoki P. Medicine (Baltimore). 1992 Jan; 71(1):1-13.
|
1549056 |
| Porphyria Drug Lists | ||
| 2. | French List
Centre Français des Porphyries
|
|
| 3. | EPI List
European Porphyria Initiative No longer maintained
|
|
| 4. | South African List
Porphyria South Africa No longer maintained
|
|
Tradenames
Aerocrom 
Ipratropium /Salbutamol 
Limitox · Muxol · Neumolex · tos-xol 
Combipramol · Combivent · Ipramol · Ventide 
Combivent